ASCENTAGE PHARMA GROUP INTERNATIONAL
Tremor tracks 14 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- AAPGAscentage Pharma Group Inc.10Calm
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Signing up patientsPhase 1/2123 patientsMain results: Oct 20, 2024 - AAPGAscentage Pharma Group Inc.10Calm
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
FinishedPhase 2144 patientsMain results: Aug 1, 2024 - AAPGAscentage Pharma Group Inc.0Calm
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Signing up patientsPhase 3333 patientsMain results: Jun 30, 2027 - AAPGAscentage Pharma Group Inc.0Calm
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Signing up patientsPhase 1/2100 patientsMain results: Jun 1, 2027 - AAPGAscentage Pharma Group Inc.0Calm
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Signing up patientsPhase 3344 patientsMain results: Aug 2027 - AAPGAscentage Pharma Group Inc.0Calm
A Study of Olverembatinib in SDH-deficient GIST.
Signing up patientsPhase 340 patientsMain results: Mar 31, 2027 - AAPGAscentage Pharma Group Inc.0Calm
Global Trial in APG2575 for Patients With CLL/SLL
Signing up patientsPhase 3400 patientsMain results: Dec 31, 2026 - AAPGAscentage Pharma Group Inc.0Calm
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Signing up patientsPhase 3350 patientsMain results: Dec 31, 2027 - AAPGAscentage Pharma Group Inc.0Calm
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Signing up patientsPhase 1/2682 patientsMain results: Sep 2028 - AAPGAscentage Pharma Group Inc.0Calm
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Signing up patientsPhase 275 patientsMain results: Dec 2026 - AAPGAscentage Pharma Group Inc.0Calm
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Signing up patientsPhase 3486 patientsMain results: May 25, 2028 - AAPGAscentage Pharma Group Inc.0Calm
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Signing up patientsPhase 278 patientsMain results: May 31, 2026 - AAPGAscentage Pharma Group Inc.0Calm
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Running, no new patientsPhase 1/2230 patientsMain results: Dec 30, 2025 - AAPGAscentage Pharma Group Inc.0Calm
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Signing up patientsPhase 1/295 patientsMain results: Apr 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- None in the last 12 months.